LENZ TherapeuticsvsMerck & Company

LENZ and MRK stock compared: price, dividend, valuation and results, from SEC filings.

LENZ

LENZ Therapeutics, Inc.

$2.96

Value $93M

-11.23%
LENZ's page

MRK

Merck & Company, Inc.

$133.72

Value $331B

+0.69%
MRK's page

LENZ Therapeutics (LENZ) has a market value of $93M and Merck & Company (MRK) $331B. Over the last year, with dividends, LENZ moved -89.6% and MRK +44.8%. Dividend yield: LENZ none, MRK 2.54%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    LENZ$93M

    MRK$331B

    MRK is 3,556 times LENZ

  • Revenue, 12 months

    LENZ$12M

    MRK$67.4B

    MRK is 5,452 times LENZ

  • Net income, 12 months

    LENZ-$140M

    MRK$2.5B

  • Operating margin

    LENZ-1,211.2%

    MRK–

  • ROIC

    LENZ-52.1%

    MRK3.9%

    55.9 points apart

  • P/E

    LENZ–

    MRK134.8

  • Dividend yield

    LENZ0.0%

    MRK2.5%

    2.5 points apart

  • 5-year return

    LENZ-92.8%

    MRK+93.0%

    185.8 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

LENZ-92.8%

MRK+93.0%

010020020222023202420252026
Returns by period
PeriodLENZWith dividendsMRKWith dividends
1 year since November 19, 2025-89.6%Price -89.6%+44.8%Price +40.7%
3 years since November 20, 2023-66.0%-30.2% a yearPrice -82.0%+42.7%+12.6% a yearPrice +30.2%
5 years since November 19, 2021-92.8%-40.9% a yearPrice -96.2%+93.0%+14.1% a yearPrice +65.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

LENZLENZ TherapeuticsMRKMerck & Company

Valuation

LENZMRK
Valuation
Price$2.96$133.72
Market value$93M$331B
Enterprise value (EV)–$375B
P/E–134.8
P/E, 5-year median–14.8
P/B0.57.4
EV/EBIT–78.7
Free cash flow yield–4.5%

Results and growth

LENZMRK
Results and growth
Revenue, 12 months$12M$67.4B
Net income, 12 months-$140M$2.5B
Free cash flow, 12 months-$128M$14.7B
Earnings per share, 12 months-$4.53$0.98
Revenue growth, year on year–1.3%
Revenue growth a year, past–+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

LENZMRK
Margins and returns on capital
Gross margin82.0%71.8%
Operating margin-1,211.2%–
Net margin-1,135.0%3.6%
ROIC-52.1%3.9%
ROE-61.7%5.2%

Balance sheet

LENZMRK
Balance sheet
Cash$197M$9.7B
Total debt$460.0K$53.8B
Net debt / EBITDA–5.7
Interest cover–2.4×

Dividends and buybacks

LENZMRK
Dividends and buybacks
Dividend yield–2.5%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.5%
Shareholder yield–4.1%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: LENZ or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, LENZ Therapeutics or Merck & Company?

By market value, Merck & Company ($331B) is about 3,556.2 times LENZ Therapeutics ($93M), at today's prices.

How did LENZ and MRK stock do over the last 5 years?

Since November 19, 2021, LENZ's price moved -96.2% and MRK's +65.7%. With dividends: LENZ -92.8% (-40.9% a year), MRK +93.0% (+14.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, LENZ or MRK?

The dividend yield at today's price is none for LENZ Therapeutics and 2.54% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which has the higher profit margins, LENZ Therapeutics or Merck & Company?

Over the last twelve months, the net margin was -1,135.0% for LENZ Therapeutics and 3.6% for Merck & Company, and the operating margin -1,211.2% and –. Revenue was $12M and $67.4B.

Which is the better investment, LENZ Therapeutics or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.